BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications.
The Company’s commercial product, IGALMI™ (dexmedetomidine) sublingual film (developed as BXCL501), is approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The safety and effectiveness of IGALMI have not been established beyond 24 hours from the first dose. For more information, please visit igalmi.com and also see the IGALMI full Prescribing Information.
BXCL501 is under evaluation for at-home use for the acute treatment of agitation associated with Alzheimer’s dementia and for the acute treatment of agitation associated with bipolar disorders or schizophrenia. The safety and efficacy of BXCL501 for these uses have not been established. The Company is also developing BXCL502 as a potential therapy for chronic agitation in dementia. The safety and efficacy of BXCL502 have not been established.